RPE

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Health Technology, Clinical Trials, Webcast, RPE, Interest, B2M, Research, VAC, D, Therapy, Visual acuity, OCT, IND, Lineage Cell Therapeutics, Eterna, INL, Patient, FDA, Collaboration, G&A, OPL, Expense, Investigational New Drug, NYSE American, Trial of the century, ELM, AMD, Geographic atrophy, Roche, Survival, Partnership, Congress, Letter, TASE, NK, Pharmaceutical industry, Fine chemical, Vaccine, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Amcor and NOVA Chemicals announce agreement to source mechanically recycled polyethylene

Retrieved on: 
Wednesday, November 8, 2023
ASX, RPE, Recycling, Environment, MOU, AMC, Nova Chemicals, Plastic, Nova, NYSE, AMCR, Bottled water, Lumber, Amcor

DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films. Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.

Key Points: 
  • DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films.
  • Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.
  • The supply agreement would enable Amcor to purchase SYNDIGO™ rPE resin, manufactured at NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, which is projected to be in operation as early as 2025.
  • The recycling facility was announced in July as a significant expansion of NOVA Chemicals' Circular Solutions business.

Amcor and NOVA Chemicals announce agreement to source mechanically recycled polyethylene

Retrieved on: 
Wednesday, November 8, 2023
ASX, RPE, Recycling, Environment, MOU, AMC, Nova Chemicals, Plastic, Nova, NYSE, AMCR, Bottled water, Lumber, Amcor

DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films. Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.

Key Points: 
  • DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films.
  • Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.
  • The supply agreement would enable Amcor to purchase SYNDIGO™ rPE resin, manufactured at NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, which is projected to be in operation as early as 2025.
  • The recycling facility was announced in July as a significant expansion of NOVA Chemicals' Circular Solutions business.

Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment

Retrieved on: 
Tuesday, October 24, 2023
Vance DeGeneres, FDA, IND, Food, Hope, AMD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, MBA, Geographic atrophy, Cell, Retinitis pigmentosa, Iris (anatomy), EA, RPE, GA, Regenerative medicine, Therapy, Patient, SAN, Investigational New Drug, Pharmaceutical industry, Management

The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.
  • This innovative compound offers hope to patients battling geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).
  • Endogena Therapeutics remains dedicated to its mission of unlocking the body's regenerative potential and making a meaningful impact on patients' lives.
  • This latest achievement reinforces the company's commitment to advancing innovative therapies for conditions that urgently require novel treatment options.

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Janus, Medical Affairs Bureau, Lineage Cell Therapeutics, AMD, AAO, Cell, Geographic atrophy, OD, RPE, Division, San Francisco Marriott Marquis, American Academy, GA, American Academy of Ophthalmology, Lineage, Annual general meeting, Macular degeneration, Roche, TASE, CFA, NYSE American, San Francisco, Therapy, Patient, Food and Drug Administration, Pharmaceutical industry, Ophthalmology, Genentech

In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .

Key Points: 
  • In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .
  • Eyecelerator will occur prior to the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and will be held at the San Francisco Marriott Marquis on Thursday, November 2nd, 2023.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting

Retrieved on: 
Thursday, October 19, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Gene editing, Retinal pigment epithelium, Mouse, Dawn, RNA, ARMM, Histopathology, ARMM Regional Legislative Assembly, RPE, Disease, Cell death, Cytotoxicity, Therapy, Kupffer cell, Retina, Vaccine

Specifically, the Company presented new data demonstrating retinal biodistribution of engineered ARMMs across multiple species – including non-human primates – and data demonstrating successful in vivo functional delivery of a Cas9/guide RNA gene editing complex.

Key Points: 
  • Specifically, the Company presented new data demonstrating retinal biodistribution of engineered ARMMs across multiple species – including non-human primates – and data demonstrating successful in vivo functional delivery of a Cas9/guide RNA gene editing complex.
  • The data were presented at the Cracking the Code: The Dawn of Nucleic Acid Medicines meeting, taking place October 17-19, 2023, in Worcester, MA.
  • “We have shown that our ARMM technology can successfully deliver functionally active gene editing complexes to Kupffer cells and ameliorate disease in an acute liver injury model.
  • Additional data in mice, minipigs, and non-human primates demonstrated the efficient delivery of subretinally administered ARMMs to the RPE and photoreceptors, cell types associated with multiple retinal diseases.

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

Retrieved on: 
Wednesday, October 11, 2023
Health, Other Science, Clinical Trials, Science, Pharmaceutical, Optical, Biotechnology, Patent, Lineage Cell Therapeutics, Iris (anatomy), Roche, Lineage, Therapy, AMD, NYSE American, GA, Growth, TASE, RPE, Patient, Geographic atrophy, Pharmaceutical industry, Genentech

11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.

Key Points: 
  • 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.
  • The patent, which has been exclusively licensed to Lineage, has an expected expiration date of July 28, 2036.
  • Subretinal delivery of OpRegen has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • The program is being developed under an exclusive worldwide collaboration between Lineage, Roche , and Genentech , a member of the Roche Group.

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Thursday, October 5, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Congress, Lineage Cell Therapeutics, Tel Aviv Sourasky Medical Center, Letter, Trial of the century, Cell, Maintenance, OPL, OCT, Therapy, AMD, NYSE American, GA, INL, TASE, RPE, Patient, Geographic atrophy, ELM, Fine chemical, Medical imaging, Genentech, Ophthalmology, Lineage

RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • “We are extremely pleased to see these additional observations of rapid improvements to outer retinal structure in the initial clinical study of OpRegen.
  • Durability of retinal structure improvements beyond the 12-month primary endpoint is still being evaluated in other patients.

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

Retrieved on: 
Wednesday, September 13, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Lineage, AMD, Geographic atrophy, GA, Cell, RAI Amsterdam, Congress, Patient, TASE, Tel Aviv Sourasky Medical Center, NYSE American, Lineage Cell Therapeutics, RPE, Therapy, Pharmaceutical industry, Fine chemical, Genentech, Ophthalmology

The meeting will be held in the RAI Amsterdam, The Netherlands from October 5-8, 2023.

Key Points: 
  • The meeting will be held in the RAI Amsterdam, The Netherlands from October 5-8, 2023.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • It is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (ClinicalTrials.gov Identifier: NCT05626114 ).

NOVA Chemicals Announces Company’s First Mechanical Recycling Facility, Operated by Novolex

Retrieved on: 
Tuesday, July 18, 2023
NOVA, Plastic, Hoosier, Cambridge Institute for Sustainability Leadership, AB, Nova Chemicals, Recycling, RPE, Nova, Chemical substance, Bottled water, Renewable energy

CALGARY, AB, July 18, 2023 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) has made a significant expansion of its Circular Solutions business today by announcing an investment into developing its first mechanical recycling facility in Connersville, Ind.

Key Points: 
  • CALGARY, AB, July 18, 2023 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) has made a significant expansion of its Circular Solutions business today by announcing an investment into developing its first mechanical recycling facility in Connersville, Ind.
  • “NOVA Chemicals continues to show clear leadership in reshaping plastics for a better, more sustainable world,” said NOVA Chemicals President and CEO, Roger Kearns.
  • The collaboration will increase the speed with which NOVA Chemicals ramps up its supply of SYNDIGO rPE to the market.
  • “Novolex is proud to collaborate with NOVA Chemicals’ Circular Solutions and is excited by the opportunity to operate this state-of-the art recycling facility in the Hoosier state,” said Novolex Chairman and CEO, Stanley Bikulege.